Discover how AI-based assays offer a promising approach to tailor treatment for high-risk non-muscle-invasive bladder cancer.

J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Adjuvant, intravesical bacillus Calmette–Guérin (BCG) therapy reduces the risk of recurrence and progression of superficial bladder cancer, but confers a considerable risk of local and systemic ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

(UroToday.com) The 2025 SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Peter Clark discussing a first-in-human study of TAR-210 erdafitinib intravesical system in ...

An artificial intelligence platform may help identify BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) and steer alternative treatment.

SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...